Company Overview - The company has conducted a recent survey and engaged in in-depth discussions with management regarding strategic reviews, new product performance, and international expansion [1] - In 2025, the company plans to conduct large-scale new product launches to experiment, while in 2026, it aims to focus on trending categories to enhance performance certainty, with a continued emphasis on new product categories and international performance [1] Strategic Focus - In 2026, the company intends to concentrate on key product categories, which is expected to improve quality and efficiency. In 2025, the company explored business boundaries with a global strategy, achieving good performance in the 9.9 yuan market segment, while some categories, such as female-oriented products, did not meet internal targets, leading to resource dispersion and profit drag [1] - The company plans to stabilize the new product launch rhythm and improve the success rate of individual products, while financial maturity and stable personnel size are expected to reveal operational leverage effects [1] - The company anticipates stabilizing and recovering gross margins by controlling the proportion of low-margin products and leveraging scale effects to dilute costs [1] Product Development - The company has successfully cultivated the building block vehicle category, which is expected to drive future growth. In 2026, it plans to maintain a monthly launch rhythm for this category, which is expected to contribute positively to gross margins [1] - The core IP operation for building block figures continues to deepen, with the Transformers series effectively covering price ranges from 9.9 yuan to 249 yuan, while new SKU specifications for Ultraman stimulate demand [1] - The company’s strategy for all demographics is progressing, with an expected increase in the proportion of adult-oriented products in the second half of 2025 [1] International Expansion - The company’s overseas business is expected to continue high growth, with a projected doubling in the second half of 2025. The pricing strategy and product strength have allowed the company to maintain a price advantage despite North American tariff impacts, successfully entering mainstream channels like Walmart [2] - North America is expected to become the largest single overseas market in 2026, while the company plans to expand its presence in Southeast Asia, particularly in Thailand and Vietnam, supported by logistics and warehousing [2] - The European team is still being built, indicating significant future potential in that market [2] Financial Forecast and Valuation - Due to some new products underperforming, the company has lowered its adjusted net profit forecasts for 2025 and 2026 by 19% and 17% to 650 million yuan and 870 million yuan, respectively, and introduced a new adjusted net profit forecast of 1.07 billion yuan for 2027 [2] - The current price corresponds to 18 and 15 times the adjusted P/E for 2026 and 2027, respectively. The target price has been reduced by 26% to 100 HKD, corresponding to 26 and 20 times the adjusted P/E for 2026 and 2027, indicating a potential upside of 40% from the current price [2]

Core Viewpoint - The company adopts a "dual-track" strategy for its international expansion, focusing on both licensing out innovative products to mature markets and direct exports to emerging markets to establish a global sales network [1] Group 1: Licensing Strategy - The company is currently focusing on overseas rights cooperation for its core product, Lecanemab, in the self-immune field, which has attracted attention from multiple overseas pharmaceutical companies due to its clinical efficacy and low dosing frequency [1] - The partnership with XinKang allows for shared overseas rights, enhancing the product's market potential [1] Group 2: Export Strategy - The company has systematically laid out its export strategy since 2022, prioritizing Southeast Asia and South America as key emerging markets [1] - The decision is based on three core considerations: 1. Regional driving effect, using Vietnam and Brazil as pivotal points to accelerate market expansion due to their robust drug regulatory systems [1] 2. Registration synergy, as Southeast Asian countries generally recognize or can reference Chinese clinical research data, speeding up the approval process [1] 3. Market growth potential, with Vietnam's pharmaceutical market maintaining double-digit growth and Brazil being the largest pharmaceutical market in Latin America [1] Group 3: Implementation Measures - In Southeast Asia, the company is building a localized production and sales platform through the acquisition of the Vietnamese listed company IMP [1] - In South America, the focus is on Brazil, actively promoting product registration and channel development, leveraging its efficient review process to accelerate product entry [1] - The company expects that through 2-3 years of strategic layout and cultivation, its overseas formulation business will gradually scale up and contribute positively to financial performance in the future [1]

Group 1 - The core viewpoint of the article highlights a positive trend in Chinese technology stocks, driven by overnight gains in the US stock market, with significant increases in Hong Kong's technology ETFs [1] - The Hong Kong Technology 50 ETF (159750) and the Hong Kong Stock Connect Technology ETF (159125) saw increases of 0.95% and 0.65% respectively, with intraday highs of 1.52% and 1.29% [1] Group 2 - Goldman Sachs' Chief China Equity Strategist Liu Jinjun projects a target of 100 points for the MSCI China Index and 5200 points for the CSI 300 Index by the end of 2026 [2] - The expected return rate for the Chinese stock market in 2026 is estimated to be between 15% and 20%, primarily driven by earnings growth, with a projected earnings growth rate of 14% for Chinese stocks [2] Group 3 - Three main factors are identified to drive earnings growth in Chinese stocks: 1. The AI industry is expected to contribute significantly, with annual contributions of 2% to 3% to overall market earnings growth over the next 3 to 5 years as the focus shifts from computing power to application and commercialization [2] 2. The overseas strategy shows potential, as companies listed in the US S&P 500 have 28% of their revenue from overseas, compared to only 16% for Chinese companies, indicating substantial room for growth [2] 3. The "anti-involution" trend is also anticipated to positively impact earnings growth [3]

Business Overview - Lizhu Biopharmaceuticals operates three main business segments: autoimmune, reproductive, and vaccine fields [2][3] - The core product in the autoimmune field, Lakanqita monoclonal antibody, has shown superior efficacy in clinical trials compared to competitors [4][5] Autoimmune Field - Lakanqita monoclonal antibody targets IL-17A/F dual sites, with a PASI100 response rate of 49.5% in clinical trials, outperforming the control group at 40.2% [4] - The product is expected to receive approval by the end of 2026, with significant market potential due to its unique characteristics [5] Reproductive Field - The recombinant human follicle-stimulating hormone (r-FSH) injection is anticipated to be approved within the year, reinforcing the company's leadership in assisted reproduction [3] Vaccine Field - The quadrivalent recombinant protein influenza vaccine is the first of its kind with an adjuvant, having completed Phase I trials and expected to enter Phase II in March [3] International Expansion Strategy - The company adopts a dual-track strategy for international expansion, focusing on licensing out innovative pipelines and direct exports to emerging markets [5][6] - Key markets include Southeast Asia and South America, with Vietnam and Brazil as strategic hubs for regulatory advantages and market growth [6] Cardiovascular Pipeline - H001, an oral direct thrombin inhibitor, is the fastest progressing project in its category, aimed at preventing venous thromboembolism (VTE) post-orthopedic surgeries [7] - The product has shown comparable efficacy to standard therapies and is preparing for Phase III trials [8] GnRH Pipeline - The GnRH pipeline covers all related indications and various formulations, making it the most comprehensive in China [9] - Key products include leuprolide with multiple formulations expected to launch soon, enhancing market presence [9] Chemical Preparation Segment - The chemical preparation segment generated revenue of 4.72 billion CNY, accounting for 51.8% of the company's total revenue in the first nine months of 2025 [10][11] - Growth drivers include product upgrades, innovation, and a focus on core therapeutic areas [11][12]

Core Viewpoint - Goldman Sachs predicts China's GDP growth rate will be 4.8% in 2026, supported by strong export growth. The MSCI China Index target is set at 100 points, and the CSI 300 Index target is 5200 points by the end of 2026. Net inflows from southbound funds are expected to reach $200 billion (approximately 1.4 trillion yuan), a new record high [1][9]. Export Support Factors - China's export growth is projected to maintain a rate of 5%-6%, significantly higher than the global trade growth of 2%-3%. This forecast is based on three core factors: steady global economic recovery boosting demand, China's cost advantages across various industries, and unique capabilities in rare earths and supply chains, making it difficult for international tariffs to be imposed [2][11]. - The negative impact of the real estate sector on economic growth is expected to diminish over time, with the most significant effects occurring in 2024 and 2025. As the market size shrinks, the downward pressure on GDP growth will lessen [2][11]. Currency Outlook - The RMB is expected to appreciate moderately, with an estimated undervaluation of about 25%. By the end of 2026, the RMB/USD exchange rate is projected to reach 6.85, further strengthening to 6.54 by the end of 2027, indicating an annual appreciation of approximately 2%-3% [3][11]. Stock Market Valuation and Returns - The dynamic P/E ratios for the MSCI China Index and CSI 300 Index have returned to historical averages, at approximately 13 times and 15 times, respectively. The expected stock market return for 2026 is between 15%-20%, primarily driven by earnings growth, with a projected earnings growth rate of 14% [4][12]. - Three main factors are anticipated to drive earnings growth: contributions from the AI industry, expansion into overseas markets, and positive impacts from the "anti-involution" trend [4][12][13]. Liquidity Support - Net inflows from southbound funds are expected to reach $200 billion (approximately 1.4 trillion yuan), reflecting increased demand for stock allocations from domestic individuals and institutions [6][14]. - There is still room for improvement in overseas fund allocations to Chinese stocks, which currently account for less than 8% of total risk exposure among hedge fund clients tracked by Goldman Sachs. Recent communications indicate a growing interest from overseas investors in Chinese investments [6][14]. - Personal investors are projected to contribute approximately 2 trillion yuan to the stock market over the next 12 months, driven by expectations of stock returns between 10%-15% and improved inflation expectations [6][14]. Sector Preferences - Goldman Sachs maintains a high allocation recommendation for AI and technology hardware, reflecting strong confidence in the AI narrative. The materials sector is also favored, while insurance is newly recommended for overweight allocation due to its potential for higher investment returns in a slow bull market and attractive dividend characteristics [8][15]. Policy Focus - The concept of "investing in people" is highlighted as a key policy direction, expected to manifest in various initiatives, including annual childcare subsidies of 3600 yuan. This focus is anticipated to continue and expand, covering the entire life cycle from birth to retirement, with policy support likely to strengthen to improve living standards and increase birth rates [8][16].

【导读】高盛研判 2026 年中国经济和股市 中国基金报记者 吴娟娟 1 月 20 日，高盛首席中国经济学家闪辉在媒体会上表示， 2026 年预计中国 GDP 增速为 4.8% ，出口保持强劲增长为经济提供支撑。高盛首席中国股票策略师刘劲津预计 MSCI 中 国指数年底目标点位为 100 点，沪深 300 指数年底目标点位为 5200 点。 2026 年，南向 资金净流入预计达 2000 亿美元（约 1.4 万亿元），再创新高。 出口有三大支撑 闪辉表示，过去 25 年来，中国在全球贸易中的地位发生了巨大变化。从 2000 年占美国进 口比例的 7.5% ，一路攀升至超过 20% 。 2018 年之后，中国主动进行贸易对手多元化， 中国出口占美国进口比例回到 7.5% 。 谈及未来出口走势，闪辉预测未来几年中国出口增速将维持在 5%—6% ，显著高于全球贸易 2%—3% 的增速。这一判断基于三大核心因素。 首先，全球经济稳步回升，商品需求提振。其次，中国商品在成本方面仍具优势，不同行业 领域的成本均低于竞争对手。第三，中国在稀土及供应链领域具有独特能力，国际上对华施 加关税的难度增加。 谈及人民币汇率，闪辉认 ...

Investment Rating - The report initiates coverage with a rating of "Buy" for Qianjiang Motorcycle [5][12] Core Insights - The motorcycle industry is transitioning towards high-quality development, with increasing industry concentration. Qianjiang Motorcycle is enhancing its brand matrix and accelerating its international expansion [2][22] - The company holds the leading market share in large-displacement motorcycles, with a comprehensive brand portfolio including Benelli, QJMOTOR, and Qianjiang, covering engine displacements from 50cc to 1200cc [12][22] - The company is expected to achieve significant revenue growth, with projected total revenue of CNY 6.03 billion in 2024, representing an 18.3% year-over-year increase [4][22] Financial Summary - Total revenue projections for Qianjiang Motorcycle are as follows: - 2023: CNY 5.098 billion - 2024: CNY 6.031 billion - 2025: CNY 5.478 billion - 2026: CNY 6.300 billion - 2027: CNY 7.243 billion - Net profit (attributable to the parent company) is projected to be: - 2023: CNY 464 million - 2024: CNY 677 million - 2025: CNY 505 million - 2026: CNY 562 million - 2027: CNY 650 million [4][12] - Earnings per share (EPS) estimates are: - 2023: CNY 0.88 - 2024: CNY 1.29 - 2025: CNY 0.96 - 2026: CNY 1.07 - 2027: CNY 1.23 [4][12] Market Position and Strategy - Qianjiang Motorcycle's domestic sales of fuel motorcycles are projected to remain stable, with a total of 212,000 units sold in 2024, maintaining its leading market share [26][34] - The company is focusing on expanding its international market presence, with overseas revenue expected to reach CNY 2.74 billion in 2024, a 32.5% increase year-over-year [30][34] - The company has established a robust marketing network with nearly 3,000 dealerships domestically and is expanding its international footprint in over 130 countries [12][22] Product Development and Innovation - Qianjiang Motorcycle is committed to high-performance motorcycle technology research and development, with significant investments in R&D, totaling CNY 366.4 million in 2024, which is 6.1% of its revenue [36][39] - The company is actively developing all-terrain vehicles and electric motorcycles, aligning with the trend towards new energy vehicles [12][22]

Core Insights - The forum focused on the theme "Domestic Demand as the Main Driver, Strengthening Growth: Starting a New Journey in the 14th Five-Year Plan" [1] - Liu Qiao analyzed the "mystery of China's consumption rate," highlighting that the GDP share of household consumption is only about 40%, significantly lower than the average of developed countries, despite per capita physical consumption being much higher than the global average [3][5] Group 1 - The contradiction in China's consumption is attributed to low prices and an imbalanced consumption structure, where intense competition from strong production capacity leads to low prices and profits, thereby limiting income growth and creating a vicious cycle [3][5] - Policies to boost consumption should effectively target residents' endogenous consumption decisions, integrating "investment in people" with "investment in goods" [3][5] Group 2 - Recommendations include optimizing GDP accounting to increase indicators for household income and consumption rates, implementing reforms in the distribution system, enhancing property income, and promoting new urbanization to raise disposable income [3][5] - A more proactive fiscal policy is suggested to enhance support for consumption, alongside encouraging enterprises to shift from "scale expansion" to "innovation-driven" strategies, improving profitability and distribution through overseas expansion [3][5] - Liu Qiao emphasized the need for innovative practices in the consumption sector, using electronic consumption vouchers as an example, to activate residents' endogenous consumption power and inject sustainable momentum into economic growth [3][5]

Core Viewpoint - The company, Hive Energy, emphasizes its strategy of expanding into overseas markets as a critical component for survival and growth, given the anticipated stagnation of the domestic battery market until 2026 [1][5]. Group 1: Market Strategy - Hive Energy aims to achieve a battery shipment volume of 41 GWh by 2025, representing a 53% year-on-year increase, with overseas shipments exceeding 30% for the first time [4]. - The company has identified key international clients, including Stellantis, a joint venture of Great Wall Motors and BMW, and Vietnam's VinFast, which together account for a 6% increase in shipment volume compared to 2024 [4]. - The company plans to focus on sales expansion in the Asia-Pacific, Europe, and Africa, targeting major clients and large-scale energy storage projects [7]. Group 2: Operational Goals - By 2026, Hive Energy expects to reach a shipment volume of 61 GWh, a 50% increase, with overseas business maintaining over 30% of total shipments [8]. - The company has established a dedicated overseas team of approximately 200-300 employees across various functions, including sales, technology, and legal compliance [7]. Group 3: Challenges and Responses - Hive Energy faces challenges from changes in export tax policies, trade barriers, and intellectual property issues, which could impact profit margins [9]. - The company plans to negotiate with clients to share the increased costs due to policy changes, while also considering localizing some production to mitigate these challenges [10][12]. - The company has already established an overseas production base in Thailand, focusing on electric vehicle battery packs and planning to upgrade to local production of energy storage and cells [13]. Group 4: Financial Performance - After years of losses, Hive Energy achieved its first quarterly profit in the last quarter of the previous year, with a goal to achieve full-year profitability by 2026 [14]. - The company acknowledges that rising raw material prices pose a significant uncertainty, which may affect its ability to pass costs onto customers [16].

Core Viewpoint - The company aims to accelerate its overseas expansion strategy with the goal of building a world-class brand, focusing on five major sales regions including Central Asia, Southeast Asia, the Americas, Central and Eastern Europe, and Africa [2] Group 1: Overseas Expansion Strategy - The company has identified five primary sales regions for its overseas business, which are Central Asia, Southeast Asia, the Americas, Central and Eastern Europe, and Africa [2] - The European Union is also included in the company's overseas business layout, with specific certification requirements for tractor products [2] Group 2: Product Development and Competition - The company plans to expedite product upgrades and enhance its technological research and development efforts to meet international advanced standards [2] - The company aims to actively participate in international competition within the EU market for its tractor products [2]